Clinical Trial
Share your love
Robot Radiotherapy Could Improve Treatment for AMD
Researchers from King’s College London, in collaboration with doctors at King’s College Hospital NHS Foundation Trust, have achieved a breakthrough in treating a debilitating eye disease using a new robot system. This system targets wet neovascular age-related macular degeneration (AMD)…
Australia’s 2nd Generation Bionic Eye Shows Promise in RP
Australia’s second-generation bionic eye has demonstrated “substantial improvement” in functional vision, daily activities, and quality of life for four participants over a period of more than two and a half years, according to the results of the first clinical trial.…
Skye Bioscience’s Next Steps After Glaucoma Trial Disappointment
Skye Bioscience’s phase 2a clinical trial of its SBI-100 ophthalmic emulsion in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) has failed to meet its primary endpoint for lowering intraocular pressure (IOP). Consequently, the company announced its decision…
Melt Pharmaceuticals Launches MELT-300 Phase 3 Program
Melt Pharmaceuticals has completed the dosing of its first patient in its phase 3 program for MELT-300, marking a crucial step in evaluating the safety and efficacy of this pioneering product. MELT-300 is a non-intravenous, non-opioid tablet comprising fixed doses…
Harrow Reveals 52-Week Data for Vevye ESSENCE-2 Study
Harrow, a leading pharmaceutical company, has revealed the encouraging results from its ESSENCE‑2 open-label extension (OLE) clinical study for Vevye (cyclosporine ophthalmic solution) 0.1%, a novel treatment for dry eye disease (DED). Study Design and Outcomes: ESSENCE-2 OLE Analysis The…
Phase 3 Trial for AZR-MD-001 in MGD Patients Begins
Azura Ophthalmics has reached a significant milestone with the enrollment of the first patient in the ASTRO study—a phase 3 clinical trial evaluating the efficacy and safety of AZR-MD-001 in patients grappling with clinical signs and symptoms of meibomian gland…
Novel Eyeglass Lens Tech Offers Relief for Migraine Patients
This spring, individuals grappling with migraines find relieve with a novel solution for managing light sensitivity, thanks to new eyeglass lens technology developed by a physician-scientist at the University of Utah John A. Moran Eye Center. The Impact of Migraine…
IND for DF-003 Cleared by FDA for ROSAH Syndrome Trial
In a significant development for the medical community, Drug Farm announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the Investigational New Drug (IND) application of DF-003. This novel drug, hailed as a first-in-class oral medication,…
USC Roski Eye Institute Investigates Promising Drugs for TED
The USC Roski Eye Institute is making significant strides in the realm of Thyroid Eye Disease (TED) treatment through pioneering clinical trials exploring new medications. TED, a condition characterized by bulging eyes and potential vision impairment, has traditionally necessitated multiple…
Exonate Adds Dr. Rafiq Hasan to Leadership Team
Exonate announced the expansion of its Board with the appointment of Dr. Rafiq Hasan as Non-Executive Director. This strategic move aims to bolster the company’s expertise in ophthalmology, particularly within the diabetic eye disease sector, as it advances its lead…